. Author manuscript; available in PMC: 2013 Oct 1.

Published in final edited form as: J Immunol. 2011 Aug 5;187(5):2155–2161. doi: 10.4049/jimmunol.1003235

Table I. Burn patients and healthy donors enrolled in the study.

1. Healthy donors

Donor No.	1	2	3	4	5
Sex (M/F)	M	M	F	M	F
Age	35	23	45	26	25
IL-10 (pg/ml)	10	40	22	8	15

2. Acute phase burn patients^a

Patient No.	1	2	3	4	5	6	7	8	9	10
Sex (M/F)	M	M	M	M	M	F	M	F	M	F
Age	54	28	28	8	2	4	4	2	2	2
TBSA burn (%)	38	80	80	70	35	40	40	40	36	60
3rd degree (%)	38	80	80	70	35	40	40	40	36	60
2nd degree (%)	0	0	0	0	0	0	0	0	0	0
Days after burn injury^b	0	0	0	1	2	3	3	3	3	4
IL-10 (pg/ml)^c	120	76	80	145	120	220	180	250	560	868

3. Chronic phase burn patients^a

Patient No.	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
Sex (M/F)	M	M	F	M	M	F	F	M	F	F	M	M	M	M	F	M
Age	4	50	3	10	15	4	12	14	3	3	4	8	15	3	9	6
TBSA burn (%)	42	80	33	61	55	58	49	85	46	52	84	44	53	83	65	65
3rd degree (%)	42	80	33	37	45	58	34	85	46	52	74	37	53	73	65	60
2nd degree (%)	0	0	0	24	10	0	15	0	0	0	10	7	0	10	0	5
Days after burn injury^b	14	17	22	24	29	30	212	305	363	434	449	586	694	704	829	1488
IL-10 (pg/ml)^c	620	880	640	440	380	675	646	310	225	145	220	176	120	180	140	120

All patients were subjected to our standard therapeutic protocol, including early excision of burn wound, systemic antibiotic therapy, and continuous enteral feeding.

Day of blood sample collection relative to day of injury; day 0 = same day as injury, day 1 = 1 day after injury. Blood samples were taken once from each patient.

The amounts of IL-10 in sera of these patients were measured by ELISA.